Key result
Compared to healthy individuals, the risk of metabolic syndrome was significantly higher in patients with non-alcoholic fatty liver disease (OR 2.397) and alcoholic fatty liver disease (OR 4.445).
Why the study?
This study aimed to evaluate differences in the incidence of cardiovascular risk factors and metabolic syndrome between non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD).
Does fatty liver disease (NAFLD or AFLD) increase the risk of cardiovascular risk factors and metabolic syndrome compared to healthy individuals?
Observational (n=913)
No
Does fatty liver disease (NAFLD or AFLD) increase the risk of cardiovascular risk factors and metabolic syndrome compared to healthy individuals?
Odds Ratio: 2.397 (95% CI 1.365–4.208)
p-value: p=0.002
Both non-alcoholic and alcoholic fatty liver disease are associated with a similarly increased risk of metabolic syndrome and cardiovascular risk factors compared to healthy individuals, highlighting the need for cardiovascular risk assessment in all patients with fatty liver disease.
May support metabolic screening in NAFLD and AFLD; leaves open causality and should not yet change practice.
Background: This study aimed to evaluate differences between the incidence of cardiovascular risk factors and metabolic syndrome in non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) Methods: We compared the incidence of cardiovascular risk factors and metabolic syndrome between three groups of subjects (n = 913): healthy, NAFLD, and AFLD groups. The healthy group had no liver disease. Drinking quantity for diagnosis was based on a previously accepted standard. Both the NAFLD and AFLD groups comprised patients with fatty liver disease diagnosed using computed tomography (CT). Metabolic syndrome risk was compared between the NAFLD and AFLD groups. Results: No significant differences in several cardiovascular risk factors were observed between the NAFLD and AFLD groups. Upon analyzing the metabolic syndrome status in each group after making appropriate adjustments, the odds ratios (OR) in the NAFLD (OR = 2.397, P = 0.002) and AFLD groups (OR = 4.445, P = 0.001) were found to be significantly higher than that in the healthy group; the incidence rate of metabolic syndrome was similar in the NAFLD and AFLD groups. Conclusion: Both the NAFLD and AFLD groups had more cardiovascular risk factors and higher metabolic syndrome risk than the healthy group. Thus, the prevention of fatty liver disease, regardless of the specific type, should involve the identification of cardiovascular and metabolic syndrome risk factors. If abdominal CT reveals a fatty liver, whether NAFLD or AFLD, the risk of cardiovascular disease and metabolic syndrome should be assessed.
No takes yet. Share an insight, caveat, or question.
A Lum Han (2020) conducted an observational in Non-alcoholic fatty liver disease (NAFLD) and Alcoholic fatty liver disease (AFLD) (n=913). Non-alcoholic fatty liver disease (NAFLD) vs. Healthy individuals (no fatty liver) was evaluated on Metabolic syndrome (OR 2.397, 95% CI 1.365-4.208, p=0.002). Compared to healthy individuals, the risk of metabolic syndrome was significantly higher in patients with non-alcoholic fatty liver disease (OR 2.397) and alcoholic fatty liver disease (OR 4.445).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: